BRIEF published on 12/04/2025 at 06:35, 1 day 2 hours ago Formycon et MS Pharma collaborent pour le biosimilaire de Keytruda® au Moyen-Orient et en Afrique du Nord MS Pharma Keytruda® FYB206 Accord Sur Les Biosimilaires Marché MENA Partenariat Formycon
BRIEF published on 12/04/2025 at 06:35, 1 day 2 hours ago Formycon and MS Pharma Collaborate for Keytruda® Biosimilar in MENA MS Pharma Biosimilar Agreement Keytruda® FYB206 MENA Market Formycon Partnership
PRESS RELEASE published on 12/04/2025 at 06:30, 1 day 2 hours ago Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region Formycon AG and MS Pharma enter exclusive partnership to commercialize Keytruda biosimilar FYB206 in MENA region, aiming to enhance cancer drug access MENA Region MS Pharma Biosimilar Formycon Keytruda
BRIEF published on 11/24/2025 at 06:35, 11 days 2 hours ago Formycon s'associe à NTC pour la commercialisation de biosimilaires en Italie Formycon AG Ophtalmologie FYB203/Baiama® Partenariats En Matière De Biosimilaires Marché Pharmaceutique Italien
BRIEF published on 11/24/2025 at 06:35, 11 days 2 hours ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
PRESS RELEASE published on 11/24/2025 at 06:30, 11 days 2 hours ago NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization Italy Formycon AG Commercialization Eylea Biosimilar NTC
BRIEF published on 11/20/2025 at 17:05, 14 days 16 hours ago First Berlin réaffirme sa recommandation d'achat sur Formycon AG Formycon AG Dupixent Évaluation D'achat Prévisions De Recettes Biosimilaire De Keytruda
BRIEF published on 11/20/2025 at 17:05, 14 days 16 hours ago First Berlin Reaffirms Buy Rating for Formycon AG BUY Rating Formycon AG Revenue Guidance Dupixent Keytruda Biosimilar
PRESS RELEASE published on 11/20/2025 at 17:00, 14 days 16 hours ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation on Formycon AG (DE000A1EWVY8) to EUR 53 target price post Q3 results surpassing expectations and upcoming FYB206 study endpoint results First Berlin Equity Research Buy Recommendation Formycon AG FYB206 EUR 53 Target Price
BRIEF published on 11/20/2025 at 06:35, 15 days 2 hours ago Ranibizumab Biosimilar Epruvy® Launched in Germany Formycon AG Ranibizumab Biosimilar Germany Launch Ophthalmic Care
Published on 12/05/2025 at 02:35, 6 hours 44 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 8 hours 19 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 14 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 19 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 09:05, 14 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 34 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 34 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 37 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 15 hours 4 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 15 hours 19 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
